59% of US CFOs are hired from within
For many CFOs and others who are ready to assume the role, scoping out career opportunities is rarely far from mind. As such, they may benefit from keeping fresh on some basic facts about the executive hiring landscape.
For example, last year, a majority (59%) of open seats for finance chiefs in the United States were filled internally. That's according to executive search and finance consulting firm Eton Bridge Partners, which analyzed 6,400 CFO hires in the 10 countries with the greatest volume of appointments. Many were promotions from finance vice president positions.
The internal vs. external breakdown was similar in several other countries, although external hires predominated in China (55%) and Sweden (59%).
It's not necessarily a young person's game, with the average age of U.S. appointees at 51 in 2024, with 'opportunities peaking in the mid-50s,' Eton Bridge wrote in its survey report. The lowest average age was in China (46) the highest was in Japan (58).
On the other hand, a healthy proportion (29%) of the hired finance chiefs took on the title for the first time, so while boards at U.S. companies tend to prefer seasoned financial leadership, opportunities for newcomers do exist.
Despite ongoing diversity efforts, women accounted for only 20% of U.S. CFO appointments, which the report noted was slightly below benchmarks at large public companies. Major indices for such enterprises place the percentage around 25%, Eton Bridge said.
China and Sweden had the highest percentage of female CFOs, with 30% and 28%, respectively. The lowest were in Japan (4%) and India (9%).
An overwhelming majority of those hired stayed within the same sector where they had previously worked. That reversed the trend seen in 2023, when there were higher levels of sector mobility. In the United States, the 2024 proportion was 90%.
'The U.S. CFO landscape reflects a mature market where private equity influence, regulatory complexity and sector-specific growth in health care and technology demand deeply experienced, sector-literate financial leaders,' Eton Bridge wrote.
On a global basis, private equity-backed companies continued to be a 'major driver' of CFO hiring in certain markets, especially the U.S., U.K., China, Germany and Switzerland, the report noted.
But that was not the norm in other markets, such as Canada and Australia, where there were relatively few CFO moves in PE-backed settings.
Based on the current developing patterns, Eton Bridge pointed to three themes it expects to shape the CFO employment market over the next year.
Strategic stretch in the CFO remit. As the line between CFO and COO continues to blur, 'finance leaders who can own operational transformation, digital agendas, or even people-related functions will be in high demand.'
A return to movement. Citing a reopening of private equity pipelines, Eton Bridge predicted there will be an uptick in CFO transitions this year, especially in Europe.
Progress, but not parity, on diversity. 'We expect continued board-level focus on improving female representation at the CFO level, but delivery experience will still be the decisive factor.
Recommended Reading
Small Business Optimism Declines to 89.0 in April
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
3 Asian Stocks Estimated To Be Trading At Up To 38.4% Below Fair Value
As global markets respond positively to new trade deals and economic indicators, Asian stocks are capturing attention with their potential value. In this environment, identifying undervalued stocks can offer opportunities for investors seeking to capitalize on discrepancies between market prices and perceived intrinsic values. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Zhuhai CosMX Battery (SHSE:688772) CN¥14.07 CN¥27.82 49.4% SpiderPlus (TSE:4192) ¥498.00 ¥993.27 49.9% Shenzhen Envicool Technology (SZSE:002837) CN¥31.65 CN¥62.15 49.1% Range Intelligent Computing Technology Group (SZSE:300442) CN¥51.51 CN¥101.65 49.3% Polaris Holdings (TSE:3010) ¥221.00 ¥433.91 49.1% HL Holdings (KOSE:A060980) ₩40950.00 ₩81254.09 49.6% HDC Hyundai Development (KOSE:A294870) ₩23000.00 ₩45711.05 49.7% GEM (SZSE:002340) CN¥6.68 CN¥13.13 49.1% Forum Engineering (TSE:7088) ¥1206.00 ¥2404.16 49.8% cottaLTD (TSE:3359) ¥433.00 ¥851.54 49.2% Click here to see the full list of 263 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Sanil Electric Overview: Sanil Electric Co., Ltd. manufactures and sells transformers in Korea and internationally, with a market cap of ₩3.01 billion. Operations: Sanil Electric's revenue is primarily derived from its Electric Equipment segment, totaling ₩362.18 million. Estimated Discount To Fair Value: 10.5% Sanil Electric, trading at ₩98,900, is considered undervalued with a fair value estimate of ₩110,444.76. The company's earnings are projected to grow significantly at 23.7% annually over the next three years, outpacing the Korean market average of 20.9%. Revenue growth is also expected to exceed market averages at 22.4% per year. Despite high non-cash earnings and a strong forecasted return on equity of 27%, its undervaluation margin remains modest at 10.5%. The analysis detailed in our Sanil Electric growth report hints at robust future financial performance. Dive into the specifics of Sanil Electric here with our thorough financial health report. BMC Medical Overview: BMC Medical Co., Ltd. focuses on the research, development, manufacturing, and supply of respiratory health medical equipment and consumables in China with a market cap of CN¥7.91 billion. Operations: The company's revenue primarily comes from its Surgical & Medical Equipment segment, which generated CN¥915.44 million. Estimated Discount To Fair Value: 36.1% BMC Medical is trading at CN¥88.99, significantly undervalued with a fair value estimate of CN¥139.29, offering potential for investors focused on cash flow valuation. Despite low forecasted return on equity of 10% in three years, its earnings are expected to grow robustly at 27.5% annually, outpacing the Chinese market's average growth rate. Recent product-related announcements highlight BMC's expanding international presence and innovation in digital health solutions, potentially enhancing future revenue streams. The growth report we've compiled suggests that BMC Medical's future prospects could be on the up. Delve into the full analysis health report here for a deeper understanding of BMC Medical. Fuji Overview: Fuji Corporation, with a market cap of ¥246.79 billion, manufactures and sells machines and machine tools in Japan. Operations: The company's revenue is primarily derived from its Robotic Solutions segment at ¥114.21 billion and Machine Tools segment at ¥11.09 billion. Estimated Discount To Fair Value: 38.4% Fuji, trading at ¥2808, is significantly undervalued with a fair value estimate of ¥4558.69. Its earnings are forecasted to grow at 20.8% annually, surpassing the Japanese market average. Despite a low future return on equity of 9.4%, revenue growth is expected to outpace the market at 9.5% per year. Recent completion of a share buyback program and stable dividend affirmations reflect strategic financial management aimed at enhancing shareholder value amidst leadership changes. Our growth report here indicates Fuji may be poised for an improving outlook. Click here to discover the nuances of Fuji with our detailed financial health report. Where To Now? Discover the full array of 263 Undervalued Asian Stocks Based On Cash Flows right here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A062040 SZSE:301367 and TSE:6134. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 minutes ago
- Yahoo
Undiscovered Asian Gems with Strong Potential In July 2025
As global markets reach new heights, buoyed by favorable trade deals and robust economic indicators, the Asian markets are also experiencing a wave of optimism. With recent developments in trade agreements and economic resilience, investors are increasingly looking towards small-cap stocks in Asia for their potential to capitalize on these dynamic conditions. In this environment, identifying promising companies involves assessing their ability to adapt to changing market landscapes while leveraging regional growth opportunities. Top 10 Undiscovered Gems With Strong Fundamentals In Asia Name Debt To Equity Revenue Growth Earnings Growth Health Rating AIC NA 26.88% 54.47% ★★★★★★ Toho 72.03% 6.01% 64.19% ★★★★★★ PSC 15.34% 1.17% 10.86% ★★★★★★ Nantong Guosheng Intelligence Technology Group NA 8.02% 1.71% ★★★★★★ HeXun Biosciences NA 74.95% 119.41% ★★★★★★ Zhejiang JW Precision MachineryLtd 12.36% 4.29% -22.66% ★★★★★★ Wholetech System Hitech 3.31% 15.16% 19.61% ★★★★★☆ Zhejiang Jinghua Laser TechnologyLtd 2.85% 4.02% -2.43% ★★★★★☆ Ningbo Henghe Precision IndustryLtd 66.02% 5.50% 23.91% ★★★★☆☆ Keli Motor Group 35.39% 9.99% -14.86% ★★★★☆☆ Click here to see the full list of 2601 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. We're going to check out a few of the best picks from our screener tool. Quechen Silicon Chemical Simply Wall St Value Rating: ★★★★★★ Overview: Quechen Silicon Chemical Co., Ltd. operates in the manufacture and supply of silica both in China and internationally, with a market capitalization of CN¥8.11 billion. Operations: Quechen Silicon Chemical generates revenue primarily from its Specialty Chemicals segment, amounting to CN¥2.21 billion. Quechen Silicon Chemical, a nimble player in the chemicals sector, has shown robust growth with earnings surging 23.4% over the past year, outpacing the industry's modest 4% rise. The firm is trading at a compelling value, sitting 33.4% below its estimated fair value. It boasts high-quality earnings and maintains an impressive debt-to-equity ratio that has shrunk from 9% to just 2.3% over five years. With strong free cash flow and profitability ensuring no worries about cash runway, Quechen appears well-positioned for continued growth with forecasts suggesting an annual earnings increase of nearly 11.82%. Click here and access our complete health analysis report to understand the dynamics of Quechen Silicon Chemical. Understand Quechen Silicon Chemical's track record by examining our Past report. HangzhouS MedTech Simply Wall St Value Rating: ★★★★★★ Overview: Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, production, sale, and service of endoscopic surgery equipment and accessories in China with a market cap of approximately CN¥6.65 billion. Operations: HangzhouS MedTech generates revenue primarily from the sale of endoscopic surgery equipment and accessories. The company's net profit margin has shown a notable trend, reflecting its financial health and efficiency in managing costs relative to its revenue streams. With no debt over the past five years, HangzhouS MedTech showcases financial prudence, underscored by high-quality earnings. The company's earnings growth of 25.9% in the last year significantly outpaced the Medical Equipment industry average of -2.2%. Trading at a value 24.8% below its estimated fair value, it offers an attractive proposition compared to peers and industry standards. Levered free cash flow has shown a steady rise, reaching US$267.89 million recently, hinting at robust operational efficiency despite capital expenditures of US$41.16 million in the same period. Future growth prospects appear promising with forecasted annual earnings growth of 20.76%. Dive into the specifics of HangzhouS MedTech here with our thorough health report. Explore historical data to track HangzhouS MedTech's performance over time in our Past section. Medprin Regenerative Medical Technologies Simply Wall St Value Rating: ★★★★★★ Overview: Medprin Regenerative Medical Technologies Co., Ltd. is a company specializing in the development and manufacture of innovative regenerative medical products, with a market cap of CN¥4.96 billion. Operations: Medprin Regenerative Medical Technologies generates revenue through the development and manufacture of regenerative medical products. The company's financial performance is highlighted by a notable net profit margin, reflecting its efficiency in managing costs relative to its revenue streams. Medprin Regenerative Medical Technologies, a nimble player in the medical equipment sector, showcases impressive financial health with no debt and an earnings growth of 83.5% over the past year, outpacing the industry average of -2.2%. The company has transitioned to positive levered free cash flow recently, reaching CNY 102.39 million by mid-2025 from negative figures in prior years. Despite recent share price volatility, Medprin's strategic moves include a private placement at CNY 48.03 per share to raise funds for asset purchases and operational support, reflecting robust shareholder confidence and positioning it well for future endeavors. Delve into the full analysis health report here for a deeper understanding of Medprin Regenerative Medical Technologies. Gain insights into Medprin Regenerative Medical Technologies' past trends and performance with our Past report. Taking Advantage Take a closer look at our Asian Undiscovered Gems With Strong Fundamentals list of 2601 companies by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:605183 SHSE:688581 and SZSE:301033. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Chinese AI firms form alliances to build domestic ecosystem amid US curbs
SHANGHAI (Reuters) -China's artificial intelligence companies have announced two new industry alliances, aiming to develop a domestic ecosystem to reduce dependence on foreign tech as they seek to cope with U.S. export restrictions on advanced Nvidia chipsets. The announcements were timed to coincide with the three-day World Artificial Intelligence Conference in Shanghai ending on Monday. The conference also showcased a slew of new products, such as an AI computing system from Huawei that experts believe rivals Nvidia's most advanced offering, as well as consumer-friendly products such as several kinds of digital AI glasses. The "Model-Chip Ecosystem Innovation Alliance" brings together Chinese developers of large language models (LLMs) and AI chip manufacturers. "This is an innovative ecosystem that connects the complete technology chain from chips to models to infrastructure," said Zhao Lidong, CEO of Enflame, one of the participating chipmakers. Other manufacturers of graphics processing units (GPUs) in the alliance include Huawei, Biren, and Moore Threads, which have been hit by U.S. sanctions that block them from purchasing advanced tech made with U.S. know-how. The alliance was announced by StepFun, an LLM developer. A second alliance, the Shanghai General Chamber of Commerce AI Committee, aims to "promote the deep integration of AI technology and industrial transformation." Participants include SenseTime, also sanctioned by the U.S. and which has pivoted from facial recognition technology to LLMs. Others are StepFun and another LLM developer, MiniMax, as well as chipmakers Metax and Iluvatar CoreX. One of the most talked about products at the conference was Huawei's CloudMatrix 384 which incorporates 384 of its latest 910C chips and outperforms Nvidia's GB200 NVL72 on some metrics, according to U.S. research firm SemiAnalysis. Huawei's system design capabilities have meant that it has been able to use more chips and system-level innovations to compensate for weaker individual chip performance, SemiAnalysis said. At least six other Chinese computing firms showcased similar "clustering" chip technology. Metax demonstrated an AI supernode featuring 128 C550 chips designed to support large-scale liquid-cooled data centre requirements. Other events included Tencent's unveiling of its open-source Hunyuan3D World Model 1.0, which the company said enables users to generate interactive 3D environments through text or image prompts. Baidu announced what it said was next-generation "digital human" technology that helps businesses to create virtual livestreamers. It features "cloning technology" that can replicate a human's voice, tone, and body language from just 10 minutes of sample footage. Alibaba was among those announcing AI glasses. Its Quark AI Glasses are powered by its Qwen AI model and are due to be released in China by the end of 2025. They will allow users to access the tech giant's map service for easy navigating and to use Alipay by scanning QR codes with voice commands. Connectez-vous pour accéder à votre portefeuille